Matthew R. Henn - 08 Sep 2022 Form 4 Insider Report for Seres Therapeutics, Inc. (MCRB)

Role: Chief Scientific Officer and EVP
Signature: /s/ Thomas J. DesRosier, attorney-in-fact for Matthew R. Henn
Issuer symbol: MCRB
Transactions as of: 08 Sep 2022
Net transactions value: $0
Form type: 4
Filing time: 09 Sep 2022, 16:46:25 UTC
Previous filing: 06 Jul 2022
Next filing: 07 Feb 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MCRB	Stock Option (Right to Buy)	Award	$0	+35,000		$0.000000	35,000	08 Sep 2022	Common Stock	35,000	$10.84	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. Subject to the Reporting Person's continued service to the Issuer through each applicable vesting date, the option vests and becomes exercisable in two equal installments upon the satisfaction of certain performance criteria. On September 8, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in vesting of the option as to 35,000 shares.

Content

On June 19, 2017, the Reporting Person was granted an option to purchase 70,000 shares of the Issuer's common stock. Subject to the Reporting Person's continued service to the Issuer through each applicable vesting date, the option vests and becomes exercisable in two equal installments upon the satisfaction of certain performance criteria. On September 8, 2022, the Issuer's Board of Directors determined that the performance criteria for the first installment were met, resulting in vesting of the option as to 35,000 shares.

Remarks:

Chief Scientific Officer and EVP